Payment overview · 2025
General Payments
$1,048.99
68 reported records · 20 companies
Healthcare provider profile · identity verified
Amanda Rae Foxx, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LEXINGTON, KY · NPI 1639462989
Verified facts
What the public records show
CMS Open Payments records show Amanda Rae Foxx, M.D. received $1,048.99 in general payments during 2025 across 68 reported records.
PFIZER INC. accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Jardiance, Mounjaro, Ozempic, Paxlovid, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Bevespi Aerosphere by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $265.74 | 25.3% | 26 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $182.98 | 17.4% | 9 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $74.80 | 7.1% | 4 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $68.23 | 6.5% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $64.88 | 6.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.73 | 5.3% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $46.39 | 4.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.51 | 3.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.97 | 2.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.58 | 2.8% | 2 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.11 | 2.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $23.52 | 2.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $21.09 | 2.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.96 | 2.0% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.67 | 2.0% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.14 | 1.9% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $18.28 | 1.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.50 | 1.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.90 | 1.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.01 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,036.57 | 67 |
| Education | $12.42 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $196.89 | 22 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $133.79 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $133.79 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $88.50 | 10 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $78.82 | 10 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $74.80 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.19 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $47.60 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $46.39 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $37.58 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $37.58 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.58 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.42 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.42 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $33.51 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.97 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $29.81 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.58 | 2 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $26.11 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| VPRIV Normalized: vpriv |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 31 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 74 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 85 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 88 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 63 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 23 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 31 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
88 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
74 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 552 | 159 |
| Levothyroxine Sodium | Levothyroxine Sodium | 508 | 150 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 455 | 145 |
| Losartan Potassium | Losartan Potassium | 326 | 108 |
| Lisinopril | Lisinopril | 315 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 290 | 90 |
| Omeprazole | Omeprazole | 264 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 211 | 77 |
| Gabapentin | Gabapentin | 193 | 69 |
| Escitalopram Oxalate | Escitalopram Oxalate | 179 | 54 |
| Montelukast Sodium | Montelukast Sodium | 168 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 167 | 55 |
| Tramadol Hcl | Tramadol Hcl | 152 | 42 |
| Alendronate Sodium | Alendronate Sodium | 151 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 140 | 38 |
| Prednisone | Prednisone | 137 | 100 |
| Carvedilol | Carvedilol | 135 | 40 |
| Synthroid | Levothyroxine Sodium | 133 | 36 |
| Trazodone Hcl | Trazodone Hcl | 131 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 49 |
| Simvastatin | Simvastatin | 128 | 39 |
| Furosemide | Furosemide | 126 | 47 |
| Metformin Hcl Er | Metformin Hcl | 112 | 38 |
| Sertraline Hcl | Sertraline Hcl | 112 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 106 | 44 |
| Spironolactone | Spironolactone | 102 | 35 |
| Alprazolam | Alprazolam | 100 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 47 |
| Mounjaro | Tirzepatide | 88 | 13 |
| Meloxicam | Meloxicam | 87 | 27 |
| Jardiance | Empagliflozin | 85 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 24 |
| Eliquis | Apixaban | 74 | 27 |
| Allopurinol | Allopurinol | 73 | 22 |
| Lorazepam | Lorazepam | 69 | 21 |
| Metformin Hcl | Metformin Hcl | 69 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 67 | 56 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 64 | 16 |
| Ozempic | Semaglutide | 63 | 17 |
| Ezetimibe | Ezetimibe | 62 | 23 |
| Bupropion Xl | Bupropion Hcl | 59 | 21 |
| Potassium Chloride | Potassium Chloride | 59 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 15 |
| Famotidine | Famotidine | 55 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | 17 |
| Celecoxib | Celecoxib | 54 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 54 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 15 |
| Atenolol | Atenolol | 50 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 17 |
| Clonazepam | Clonazepam | 48 | 11 |
| Ondansetron Odt | Ondansetron | 48 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | 27 |
| Nifedipine Er | Nifedipine | 46 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 16 |
| Estradiol | Estradiol | 44 | 24 |
| Azithromycin | Azithromycin | 39 | 39 |
| Glipizide Er | Glipizide | 39 | 12 |
| Glimepiride | Glimepiride | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 36 | 11 |
| Clonidine Hcl | Clonidine Hcl | 35 | 14 |
| Metronidazole | Metronidazole | 35 | 31 |
| Valacyclovir | Valacyclovir Hcl | 35 | 21 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 34 | suppressed |
| Finasteride | Finasteride | 33 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 32 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 19 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 31 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 28 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 31 | 31 |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | 12 |
| Cephalexin | Cephalexin | 30 | 27 |
| Ipratropium Bromide | Ipratropium Bromide | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | 11 |
| Fluconazole | Fluconazole | 28 | 21 |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Cefdinir | Cefdinir | 23 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 22 |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Baclofen | Baclofen | 21 | 12 |
| Bumetanide | Bumetanide | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 19 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 15 |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 14 |
| Colchicine | Colchicine | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Trimethoprim | Trimethoprim | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,048.99 · 68 records | PFIZER INC. | ABRYSVO, AIRSUPRA, BEXSERO, COMIRNATY, ELIQUIS, FREESTYLE LIBRE 3, GIVLAARI, INJECTAFER, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PAXLOVID, PEDIARIX, PREVNAR 20, PYRUKYND, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, Tlando, VOQUEZNA, VPRIV, VYNDAMAX, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error